Physician profile
Lynn Demeter
NPI 1376180851
$1,191.12
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $864 · 2023: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.73 | 2021-2023 | |
| Novo Nordisk INC | $162.92 | 2021-2022 | |
| Lilly USA, LLC | $152.18 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.09 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $85.01 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.57 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $57.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.89 | 2022 | |
| Pfizer INC. | $42.85 | 2022-2023 | |
| Organon LLC | $35.85 | 2022 | |
| Antares Pharma, INC. | $24.13 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $22.81 | 2022 | |
| Esperion Therapeutics, INC. | $20.42 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $17.71 | 2022 | |
| Merck Sharp & Dohme LLC | $17.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.51 | 2022 | |
| Amgen INC. | $16.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.26 | 2022 | |
| Currax Pharmaceuticals LLC | $14.58 | 2021 | |
| Exact Sciences Corporation | $13.25 | 2023 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Demeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.